OMedLive

CME Speakers

 

  • Susan O'Brien, MD

    Susan O'Brien, MD

    Susan O'Brien, MD

    Associate Director for Clinical Science

    Susan O’Brien, MD, is associate director for clinical science for the Chao Family Comprehensive Cancer Center, and medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research at UC Irvine Health in Irvine, California. Specializing in hematology and medical oncology, Dr O’Brien oversees and coordinates clinical cancer research across the entire UC Irvine Health organization, with her clinical expertise being in the diagnosis and treatment of leukemia. She has been principal investigator for more than 40 funded clinical research protocols, and has authored numerous articles in peer-reviewed journals, invited articles, and book chapters and abstracts. She earned her medical degree from the University of Medicine and Dentistry of New Jersey in Newark.
  • Julie Vose, MD, MBA

    Julie Vose, MD, MBA

  • Ian W. Flinn, MD, PhD

    Ian W. Flinn, MD, PhD

    Ian W. Flinn, MD, PhD

    Director, Hematologic Malignancies Research Program

    Ian W. Flinn, MD, PhD, is the director of lymphoma research at the Sarah Cannon Center for Blood Cancer in Nashville, Tennessee, where he oversees blood cancer research throughout Sarah Cannon and its affiliates. He is also the director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology and TriStar Centennial Medical Center. Dr Flinn received his medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland, followed by an internship and residency at the University of Michigan Medical Center in Ann Arbor. He completed a fellowship in oncology and hematology, and earned a PhD in clinical investigations from Johns Hopkins University School of Medicine. Dr Flinn is board-certified in hematology and medical oncology.
  • Bradley J. Monk, MD, FACOG, FACS

    Bradley J. Monk, MD, FACOG, FACS

    Bradley J. Monk, MD, FACOG, FACS

    Professor, Gynecologic Oncology

    Bradley J. Monk, MD, FACS, FACOG, is professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, and a professor at the University of Arizona College of Medicine, both located in Phoenix. His clinical interests include the use of chemotherapy to treat ovarian and cervical carcinoma, etiology/biomarkers in gynecologic cancers, and quality-of-life aspects of cancer care. Dr Monk has authored more than 275 peer-reviewed articles and 31 book chapters, and is an active member of various professional organizations, such as the Society of Gynecologic Oncology and the American Society of Clinical Oncology. He earned his medical degree from the University of Arizona College of Medicine in Tucson.
  • Robert L. Coleman, MD, FACOG, FACS

    Robert L. Coleman, MD, FACOG, FACS

    Robert L. Coleman, MD, FACOG, FACS

    Professor and Vice Chair of Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine

    Robert L. Coleman, MD, FACOG, FACS, is a professor, vice chair of clinical research, and the Ann Rife Cox Chair in Gynecology in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center in Houston. His research interests include drug discovery and novel therapeutics for ovarian, uterine and cervical cancer, clinical trial development and statistical design, and he serves as a principal investigator (PI) or co-PI for several prospective clinical trials. Dr Coleman is the author or co-author of more than 400 scientific publications, including over 250 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks. He received his medical degree from Creighton University in Omaha, Nebraska.
  • Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Neuroblastoma Nurse Practitoner

    Jennifer Saggio, RN, MSN, CRNP, CPON, MSN, is a neuroblastoma nurse practitioner at The Children’s Hospital of Philadelphia (CHOP) in Pennsylvania, and has been a nurse practitioner in the Division of Oncology at CHOP for the past 18 years. Ms Saggio coordinates care for children with recurrent/refractory neuroblastoma, and provides consultations to physicians, nurses, and families in order to meet the complex needs of both hospitalized and ambulatory patients with neuroblastoma. Her team cares for patients who live in the Philadelphia region, those who travel from throughout the United States, and to a large population of international patients as well. She received her graduate degree from the Pediatric Acute/Chronic Care NP Program at the University of Pennsylvania in Philadelphia.
  • Erin Armideo, CRNP, RN, CPON

    Erin Armideo, CRNP, RN, CPON

    Erin Armideo, CRNP, RN, CPON

    Pediatric Oncology Nurse Pracitioner

    Erin Armideo, RN, MSN, CRNP, CPON, is a nurse practitioner at The Children’s Hospital of Philadelphia (CHOP) in Pennsylvania, where she began her career as a pediatric oncology nurse. She earned her bachelors of nursing from the Pennsylvania State University and a master’s degree in nursing from the University of Pennsylvania, Pediatric Acute Care Nurse Practitioner program. Ms Armideo has cared for patients with various types of solid tumors in both inpatient and outpatient settings. Her passion is educating patients and families about their child’s disease, treatment and side effects of treatment. She has presented in various forums, including internationally on the management of side effects related to immunotherapy, and has received awards from CHOP and the Philadelphia City Council.
  • Gregory C. Hedler, MSW, LCSW

    Gregory C. Hedler, MSW, LCSW

    Gregory C. Hedler, MSW, LCSW

    Social Worker, Cancer Center

    Gregory C. Hedler, MSW, LCSW, is a licensed clinical social worker at the Children’s Hospital of Philadelphia (CHOP) in Pennsylvania. Focusing his supportive efforts on newly diagnosed high-risk neuroblastoma, as well as relapsed or refractory neuroblastoma, he offers 13 years of experience in pediatric oncology to these patients and their families, tailoring his therapeutic interventions to meet the nuanced psychosocial needs associated with recurrent and refractory disease. Before joining CHOP, he worked at The Children's Cancer Institute at Hackensack University Medical Center in New Jersey, caring for patients with various types of childhood cancers as well as those with sickle cell disease. Mr Hedler received his master of social work from Fordham University in New York, New York.
  • Ravi Vij, MD, MBA

    Ravi Vij, MD, MBA

    Ravi Vij, MD, MBA

    Professor of Medicine, Section of BMT and Leukemia, Division of Medical Oncology

    Ravi Vij, MD, MBA, is professor of medicine in the Division of Medical Oncology, Section of Bone Marrow Transplantation and Leukemia at Washington University School of Medicine in Saint Louis, Missouri. Dr Vij’s primary academic interests include the treatment of hematologic malignancies and hematopoietic stem cell transplantation, and his research interests involve multiple myeloma and acute myeloid leukemia (AML)/myelodysplastic syndromes. He serves on numerous committees, is an author or coauthor of over 150 publications in journals, is the author of the book, Contemporary Management of Multiple Myeloma, and has served as a reviewer for publications that include Blood, Journal of Clinical Oncology, and Leukemia and Lymphoma. He received his MD from the University of Delhi, India.
  • David Dingli, MD, PhD

    David Dingli, MD, PhD

    David Dingli, MD, PhD

    Professor of Medicine, Hematology

    David Dingli, MD, PhD, is a professor of medicine within the Division of Hematology, Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. Dr Dingli’s clinical practice is dedicated to the care of patients with multiple myeloma and related disorders. His research aims to develop and optimize the use of replicating viruses for cancer therapy, with focus areas in mathematical models and clonal evolution in hematopoiesis. He has published over 200 articles and more than 200 abstracts, mostly related to multiple myeloma and its therapy. Dr Dingli earned his medical degree from the University of Malta Medical School in Guardamangia, Malta.
  • Jared Weiss, MD

    Jared Weiss, MD

    Jared Weiss, MD

    Section Chief of Thoracic and Head/Neck Oncology

    Jared Weiss, MD, is an associate professor and section chief of thoracic and head/neck oncology at the University of North Carolina School of Medicine at Chapel Hill. Clinically, Dr Weiss focuses on treating patients with head and neck cancers and lung cancers. His research concentrates on bringing new and promising treatments to patients, while focusing on outcomes such as survival and quality of life. He is vice president of cancergrace.org, a global resource with the goal of increasing patient education and family information on cancer, and serves on the executive board of the Lung Cancer Initiative. Dr Weiss received his doctor of medicine at Yale University School of Medicine in New Haven, Connecticut, and his BS in neuroscience at Brown University in Providence, Rhode Island.
  • Robert I. Haddad, MD

    Robert I. Haddad, MD

    Robert I. Haddad, MD

    Associate Professor of Medicine

    Robert I. Haddad, MD, is an associate professor of medicine at Harvard Medical School, and is Disease Center Leader of the Head and Neck Oncology Program and a member of the Department of Adult Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Dr Haddad’s research activities involve the use of induction chemotherapy for patients with locally advanced head and neck cancer and the development of novel immunotherapeutic agents for treating locally advanced disease. He is a member or several professional societies, and has been instrumental in the development, execution and publication of numerous phase II and III trials in head and neck cancer. Dr Haddad received his medical degree from St. Joseph University French School of Medicine in Beirut.
  • Matthew I. Milowsky, MD

    Matthew I. Milowsky, MD

    Matthew I. Milowsky, MD

    Section Chief, Genitourinary Oncology

    Matthew I. Milowsky, MD, is section chief of the Genitourinary Oncology Service and co-director of the Urologic Oncology Program at the University of North Carolina (UNC) at Chapel Hill Lineberger Comprehensive Cancer Center. He leads the Genitourinary Oncology Research Program, which focuses on translational science and clinical trials for patients with urologic cancers. Dr Milowsky is also the clinic medical director at North Carolina Cancer Hospital, where he serves as a member of the Executive Committee and co-chair of the Operations Committee. He has published extensively in peer-reviewed journals, written several book chapters, and was principal investigator on the American Association for Cancer Research Henry Shepard Grant for Bladder Cancer Research.
  • Matthew Galsky, MD

    Matthew Galsky, MD

    Matthew Galsky, MD

    Director of Genitourinary Medical Oncology

    Matthew Galsky, MD, is the director of genitourinary medical oncology at the Mount Sinai School of Medicine Tisch Cancer Institute in New York. Dr Galsky specializes in caring for patients with genitourinary malignancies (bladder, prostate, kidney, and testicular cancers). His research focuses on the clinical development of novel therapies for genitourinary cancers, with a particular emphasis on bladder cancer, and he regularly speaks nationally and internationally on the topic. His research has been published in numerous journals, including the Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet Oncology and Lancet, and has been funded by organizations that include the National Institutes of Health/National Cancer Institute and the Department of Defense.
  • Matthew H. Kulke, MD, MMSc

    Matthew H. Kulke, MD, MMSc

    Matthew H. Kulke, MD, MMSc

    Associate Professor of Medicine

    Matthew Kulke, MD, MMSc, is director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School in Boston, Massachusetts. Dr Kulke has played a leading role in the molecular characterization of neuroendocrine tumors and in developing new treatments for this indication, including sunitinib, temozolomide everolimus, and telotristat ethyl. He serves on the gastrointestinal cancer committee for the Cancer and Leukemia Group B, the advisory board for the European Neuroendocrine Tumor Society, and chairs the neuroendocrine tumor guidelines panel for the National Comprehensive Cancer Network. He received his MD from the University of California, San Francisco School of Medicine and his MMSc from Harvard Medical School.
  • David C. Metz, MBBCh

    David C. Metz, MBBCh

    David C. Metz, MBBCh

    Professor of Medicine

    David C. Metz, MBBCh, is a professor of medicine and associate chief for clinical affairs in the Division of Gastroenterology at the University of Pennsylvania in Philadelphia, where he is director of the Acid-Peptic Disease Program and co-director of the GI Physiology Laboratory, the Swallowing Disorders Program and the Neuroendocrine Tumor Program. His clinical research investigates Zollinger-Ellison syndrome, H. pylori infection, nonsteroidal anti-inflammatory drug gastropathy, and gastroesophageal reflux disease. He has expertise in the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. Dr Metz earned his MBBCh (MD equivalent) from the University of the Witwatersrand in Johannesburg, South Africa.